Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

3.040 -0.160 (-5.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bluebird Bio

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
The Latest Analyst Ratings for bluebird bio
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2023
Via Benzinga
Why Is Bluebird Bio (BLUE) Stock Up 17% Today?
Bluebird Bio received a major lift from JPMorgan Chase regarding its gene-editing therapeutic, sending BLUE stock flying. 
Via InvestorPlace
Should Investors Buy the Dip With Bluebird Bio Stock?
The case for buying the dip isn't exactly a slam dunk. 
Via The Motley Fool
1 Small-Cap Stock That Could Soar in 2023
Investors should think twice before initiating a position. 
Via The Motley Fool
Why Bluebird Bio Stock Is Sinking This Week
A potential regulatory delay is weighing on the biotech's stock this week. 
Via The Motley Fool
Caterpillar To Rally Over 37%? Here Are 10 Other Analyst Forecasts For Thursday
Keybanc boosted the price target for Pure Storage, Inc. (NYSE: PSTG) from $35 to $40. Keybanc analyst Thomas Blakey maintained the stock with an Overweight rating. Pure Storage shares fell 2.1% to... 
Via Benzinga
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
Cathie Wood Is Buying This Biotech Stock Like Wildfire, But Should You?
It's facing a few issues that are practically guaranteed to affect shareholder returns. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Analyst Ratings for bluebird bio
Via Benzinga
bluebird bio Earnings Perspective: Return On Capital Employed
Via Benzinga
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture recently announced an $11.55 million registered direct offering. 
Via Benzinga
1 Incredibly Undervalued Growth Stock to Buy Hand Over Fist in May
This market-beating biotech stock still has more room to run. 
Via The Motley Fool
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why First Republic Bank Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Magic Empire Global Limited (NASDAQ: MEGL) shares jumped 268% to $3.42 after dropping around 8% on Thursday. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 28, 2023
Via Benzinga
Intel, Saia, Charter Communications And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
With FDA Submission For Sickle Cell Gene Therapy, Bluebird Bio Can Potentially Have 3 Approved Products By 2023
Via Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
$2M Price Tag for Sickle Cell Gene Therapies Could Be Cost-Effective Under Certain Scenarios, Finds ICER Analysis
Via Benzinga
Nasdaq Surges 100 Points; US Producer Prices Drop In March
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.01% to 33,650.06 while the... 
Via Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday. 
Via Benzinga
What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
Both biotechs are aiming for the same markets, but they are not equally risky. 
Via The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
S&P 500 Up 1%; Bluebird Bio Shares Plummet
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining over 1% on Wednesday. The Dow traded up 0.74% to 32,632.35 while the NASDAQ rose 1.51% to 11,893.07. The S&P 500, also... 
Via Benzinga
Stocks Rise As Investors Bet On Bank Recovery
Stocks are swinging higher today, as bond yields retreat and Wall Street bets that the worst of the regional banking crisis is in the rearview mirror. 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.